B of A Securities Downgrades Xencor to Neutral with $12 PT.
ByAinvest
Wednesday, Sep 3, 2025 12:02 pm ET1min read
XNCR--
The downgrade comes as part of a broader review of several mid-cap biotechs, including Candel Therapeutics (NASDAQ:CADL) and Erasca (NASDAQ:ERAS), which were also downgraded by BofA. Xencor's development timeline for its antibody therapies has been a significant concern, with the analyst noting that the company's pipeline may face delays and increased costs.
Despite the downgrade, Xencor remains a player in the biotechnology sector, with a strong pipeline of antibody therapies. The company's focus on developing innovative treatments for various diseases continues to attract attention from investors. However, the market's current focus on near-term catalysts has made stocks like Xencor more vulnerable to downgrades.
Investors should closely monitor Xencor's upcoming clinical trials and other developments to gauge the potential for a turnaround in the stock's performance. The company's ability to deliver positive clinical data in the near term could potentially lead to a reassessment of its valuation by analysts.
References:
[1] https://seekingalpha.com/news/4491951-erasca-candle-xencor-drop-bofa-downgrades
B of A Securities Downgrades Xencor to Neutral with $12 PT.
Bank of America Securities (BofA) has downgraded Xencor (NASDAQ:XNCR) to Neutral with a price target of $12 per share, citing concerns over a lengthier development timeline for the California-headquartered antibody therapy developer [1]. The downgrade follows a broader trend of reduced optimism for clinical-stage biotechs, as the analyst argued that stocks without near-term significant readouts may struggle in the current environment.The downgrade comes as part of a broader review of several mid-cap biotechs, including Candel Therapeutics (NASDAQ:CADL) and Erasca (NASDAQ:ERAS), which were also downgraded by BofA. Xencor's development timeline for its antibody therapies has been a significant concern, with the analyst noting that the company's pipeline may face delays and increased costs.
Despite the downgrade, Xencor remains a player in the biotechnology sector, with a strong pipeline of antibody therapies. The company's focus on developing innovative treatments for various diseases continues to attract attention from investors. However, the market's current focus on near-term catalysts has made stocks like Xencor more vulnerable to downgrades.
Investors should closely monitor Xencor's upcoming clinical trials and other developments to gauge the potential for a turnaround in the stock's performance. The company's ability to deliver positive clinical data in the near term could potentially lead to a reassessment of its valuation by analysts.
References:
[1] https://seekingalpha.com/news/4491951-erasca-candle-xencor-drop-bofa-downgrades
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet